Northwire Canada EditionSaturday, July 18, 2026
Northwire
AII 19.25 +3.9% GGA 5.95 +12.3% VM 0.140 +3.7% GSR 0.365 +1.4% QCX 0.195 +0.0% EAU 0.085 +0.0% MCM 0.310 +0.0% BAT 0.100 +5.3% SFR 0.370 +68.2% FFU 0.125 +4.2% TVI 0.045 −10.0% ZNX 0.080 +0.0% TSK 1.06 +0.9% OMM 0.050 +0.0% EMO 0.320 −7.2% MDM 0.060 +0.0% AII 19.25 +3.9% GGA 5.95 +12.3% VM 0.140 +3.7% GSR 0.365 +1.4% QCX 0.195 +0.0% EAU 0.085 +0.0% MCM 0.310 +0.0% BAT 0.100 +5.3% SFR 0.370 +68.2% FFU 0.125 +4.2% TVI 0.045 −10.0% ZNX 0.080 +0.0% TSK 1.06 +0.9% OMM 0.050 +0.0% EMO 0.320 −7.2% MDM 0.060 +0.0%
Other

Cytophage Announces the Commercialization of OvaPhage in Canada Through W.L.T. Distributors Inc.

CYTO · Price

Executive Summary

  • Cytophage Technologies announced a distribution agreement with W.L.T. Distributors Inc. to sell its newly approved bacteriophage product, OvaPhage, across Canada.
  • Health Canada issued a Letter of No Objection (LONO) for OvaPhage, marking a key regulatory milestone and enabling commercial sales in the Canadian egg industry.
  • The partnership leverages WLT’s extensive poultry‑industry network to accelerate market adoption and improve food safety by reducing Salmonella on eggshells.

Key Details

  • Distribution Partner: W.L.T. Distributors Inc. (Manitoba‑based agricultural supply company).
  • Product: OvaPhage – a bacteriophage solution designed to lower Salmonella load on egg shells, offering an alternative to chemical cleaning methods.
  • Regulatory Milestone: Received Health Canada’s Letter of No Objection (LONO), one of the first approvals for a commercial bacteriophage product of this type in Canada.
  • Market Scope: Nationwide distribution across Canada; early adopters identified and packaging/labeling work underway.
  • Industry Context: Canadian egg production totaled >915 million dozen eggs in 2024 (Statistics Canada). Reducing Salmonella aligns with food‑safety goals and consumer demand for antibiotic‑free products.
  • Strategic Rationale (CEO Quote): “Our strength lies in developing scientifically advanced bacteriophage solutions… WLT provides efficient, cost‑effective marketing and distribution services… an ideal partnership.” – Dr. Steven Theriault, CEO, Cytophage Technologies.
  • Partner Statement: “Given the challenges our industry faces today, it is critical we use innovative products that are both sustainable now and adaptable well into the future.” – James Hokanson, COO, WLT.

Notable Quotes

  • “Cytophage is excited to have WLT Distributors on board to sell OvaPhage in Canada,” – Dr. Steven Theriault, CEO, Cytophage Technologies.
  • “We have been following Cytophage’s progress from R&D to commercialization and are thrilled to work with their team on sales and distribution.” – James Hokanson, COO, WLT.
Read the original news release →

More from Cytophage Technologies Ltd.